Head-to-head · WeighScore
NexLife vs ReadyRx
The verdict
NexLife takes it — 68.5/100 to 67.6/100, but only just.
NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo). ReadyRx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NexLife | ReadyRx |
|---|---|---|
| WeighScore | 68.5/100 | 67.6/100 |
| Grade | C | C |
| Scorecard rank | #149 | #168 |
| Semaglutide | $165/mo (compounded) | $179/mo (starting dose, compounded) |
| Tirzepatide | $215/mo (compounded) | $255/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #149 · C
Strengths
- LegitScript certified platform
- Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- Both semaglutide and tirzepatide at competitive pricing
- Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset
Where it loses points
- State availability not publicly disclosed
- Compounded only — no brand-name options
- Also covers hormone optimization and longevity
- Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Graded #168 · C
Strengths
- LegitScript Certified — verifiable via the badge link in the footer
- Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
- Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide
Where it loses points
- Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
- Clinicians described as licensed and board-certified, but no names or credentials published
- 5,000+ member figure comes from a directory listing, not an independent audit
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.